Form D · Biotechnology

Stingray Therapeutics, Inc.

Dallas, TX · CIK 0001759143

Offering snapshot reported May 14, 2024 · SEC filing

Reported sold
$25K
Offering amount: $5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 1, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 14, 2024Initial$25,000No comparison1SEC filing
Feb 2, 2024Initial$436,758No comparison21SEC filing
Dec 28, 2023Amendment$6,612,080$2,663,635vs Mar 31, 202352SEC filing
Mar 31, 2023Initial$3,948,445No comparison43SEC filing
May 26, 2021Amendment$1,510,272No comparisonNot reportedSEC filing
Oct 13, 2020Amendment$117,272$65,000vs Aug 13, 20206SEC filing
Aug 13, 2020Initial$52,272No comparison2SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-513216

Source: Form D, filed May 14, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Uma Bhatt Director, Executive
Scott Andrew Jordan Director, Executive, Promoter
Jonathan P. Northrup Director, Executive
Sunil Sharma Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Health Wildcatters Incubator 3000 Pegasus Park Dr., Suite 1330
Dallas, TX, 75247